CTLA4 and melanoma: Because BRAF-mutated tumors also exhibit the overexpression of genes associated with immunosuppression, such as CTLA-4 or PD-L1, immune checkpoint inhibitors, anti-CTLA-4 and anti-PD-1 have also been approved for the treatment of melanoma [110].